ABSTRACT

Objective: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. Method: Literature review with articles’ selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology. Results and conclusions: 1) The therapeutic decision should be shared with the patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 9) after therapeutic failure of a first biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathioprine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short periods of time; 12) non-steroidal anti-inflammatory drugs should always be prescribed in association with a DMARD; 13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and management of comorbidities are recommended; 19) the patient’s vaccination status should be recorded and updated; 20) endemic-epidemic transmissible diseases should be investigated and treated.

Keywords: rheumatoid arthritis, therapy, Brazil, antirheumatic agents, consensus.
INTRODUCTION

Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease that affects the synovial membrane of peripheral joints. Its prevalence is estimated at around 0.5%–1% of the population, predominantly in women, and higher incidence in the age group from 30–50 years.1,2

The main characteristic of RA is the symmetrical impairment of small and large joints, with a more frequent involvement of the hands and feet. The chronic and destructive character of the disease can lead to important functional limitation, with loss of work capacity and quality of life, unless the diagnosis is established at an early phase of the disease and clinical improvement results from treatment.3 In addition to irreversible deformity and functional limitation, patients with RA and advanced disease can have a shorter survival, confirming the severity of that disease.4,5

The costs related to RA are high, resulting from both direct (expenditure with several medications, some of which are expensive, such as biologic drugs, in addition to medical and hospital costs) and indirect (loss of personal productivity, absenteeism, and retirement due to disability for those with total work capacity loss) factors.6

Over the past 10 years, the knowledge about the pathophysiological mechanisms of RA has advanced dramatically, with the development of new therapeutic classes of drugs and the implementation of different strategies of treatment and follow-up, such as intensive control of the disease and intervention at the beginning of the symptoms.7 The initial period of the disease, especially its first 12 months (the so-called early RA),3 is considered a therapeutic window, that is, when prompt and effective pharmacological intervention can change the disease course in the long run. Those factors have resulted in RA better clinical control, with the possibility of its sustained remission.7,8

The present consensus aimed at elaborating recommendations for the management of RA, with an emphasis on treatment, considering peculiar aspects of the Brazilian socioeconomic reality. The purpose of this document was to synthesize the current position of the Brazilian Society of Rheumatology (BSR) about the subject, aiming at better educating Brazilian physicians, especially rheumatologists, on the rational therapeutic management of RA in Brazil.

TREATMENT OF RHEUMATOID ARTHRITIS

The RA treatment comprises education of patients and their families, medicamentous therapy, physical therapy, psychosocial support, occupational therapy and surgical approaches. The medicamentous therapy includes the use of nonsteroidal anti-inflammatory drugs (NSAIDs), corticoids, synthetic and biologic disease-modifying antirheumatic drugs (DMARDs), and immunosuppressive drugs.

Educational measures

Before starting any form of treatment, patients should be educated about their disease, and, particularly, about its possible evolution, therapy and prognosis. They should be instructed about inadequate information provided through several communication media, especially the Internet. Education should start on the first consultation and include the family members, so that all of them can share information on the disease, which results in better management of the medicamentous and nonmedicamentous treatments.9,10

Educational activities are essential to guarantee patients’ collaboration. Patients have the right to know about their health conditions and the available therapeutic options, and actively participate in the choices. Patients who understand their conditions and know about the medications action, the methods to prevent deformities, and the rehabilitation process, have a better clinical evolution.11

Patients should be instructed about the role played by exercises and joint protection, and specific techniques of physical therapy and rehabilitation, so that they can get more involved with such activities to prevent joint deformities. In addition, they should be educated about the possible adaptation of household appliances and modifications in the work environment.12

Because patients with RA are often followed up by a multidisciplinary team, all professionals should have the same objectives and work together harmoniously.11
Medicamentous treatment

Nonsteroidal anti-inflammatory drugs – NSAIDs

The NSAIDs are useful to reduce the inflammatory process and pain, mainly at the early phase of disease, because DMARDs do not act immediately. In addition, NSAIDs can be used when complete control of disease activity is not achieved and in disease relapse.14,15

The choice of NSAIDs should be individualized, because there is no known superiority of any drug in that class. More control, substitution, suspension, shorter use, and lower doses should be considered in the presence of clinical conditions that can be aggravated by NSAIDs, such as previous hypersensitivity to NSAIDs, systemic arterial hypertension (SAH), heart failure, renal failure, gastrointestinal disease, arterial failure, hepatopathy, and coagulation disorders.16

For patients with previous history of gastrointestinal disease, selective cyclooxygenase 2 inhibitors have lower risk as compared with other NSAIDs.17 For those at greater risk for cardiovascular disease, the use of anti-inflammatory drugs in general should be cautious.18

Corticoids

The most known and expected effect of corticoids in RA is the improvement in the inflammatory process and pain. However, there is current evidence for their indication as participants in the disease course modification in association with DMARDs.19,20

Most studies on the use of corticoids for the treatment of RA have suggested the use of prednisone or prednisolone at low doses (≤ 15 mg/day). There are no comparative studies indicating the preferential use of higher doses at the beginning of treatment.19,20

Because corticoids can cause several side effects, their use should be shortened as much as possible. If the corticoid administration is expected to last three or more months, calcium and vitamin D supplementation should be performed. Depending on the bone densitometry result, and in patients with risk factors for fractures, the use of antiresorptive drugs, such as bisphosphonates, can be considered.23 In patients who maintain active disease in few joints, intraarticular corticoid can be used at any time during treatment22 – nevertheless, one joint should not be infiltrated more than three to four times a year. In patients using concomitantly corticoid and NSAIDs, gastric protection with proton pump inhibitors is recommended.22

Disease-modifying antirheumatic drugs – DMARDs

The DMARDs should be indicated to patients from the time RA is diagnosed.23 The use of DMARDs in patients with undifferentiated arthritis and biomarkers for RA, such as positivity for anti-cyclic citrullinated peptide antibody (anti-CCP) and/or rheumatoid factor (RF), should be considered.24

Table 1 shows the most often used DMARDs in Brazil, their presentation, dosage, and considerations about treatment monitoring.20,25–94

Synthetic DMARDs

a) Methotrexate – MTX

MTX is an immunomodulatory agent, which inhibits the synthesis of DNA, RNA, thymidine, and proteins. The anti-inflammatory effects of MTX on RA seem to be related, at least partially, to the modulation of the adenosine metabolism, and to other possible effects on the tumor necrosis factor (TNF) pathways. The immunosuppressive and toxic effects of MTX are due to the inhibition of dihydrofolate reductase, the enzyme involved in the folic acid metabolism, which prevents the reduction of dihydrofolate to active tetrahydrofolate. Maximum concentration is obtained in 1–5 hours, by oral administration, and in 30–60 minutes by intramuscular (IM) or subcutaneous (SC) routes. Renal excretion of 40% to 90% of MTX in its unaltered form occurs.25

MTX is currently considered the first choice for treating RA.26 Its capacity to reduce signs and symptoms of RA activity and improve the patient’s functional status has been demonstrated.27 In addition, MTX reduces radiographic disease progression.

The initial MTX dose recommended is 10–15 mg/week, by oral or parenteral administration (IM or SC). If neither disease improvement nor disease control is observed with the initial dose, it should be progressively increased every 2–4 weeks until reaching the dose of 20–30 mg/week, preferentially in the first 12 weeks. The parenteral administration can be indicated to patients with gastrointestinal intolerance or with an inadequate response to the oral administration.28

The most frequently observed side effects are as follows: anemia, neutropenia, nausea and vomiting, mucositis, and an elevation in liver enzymes. Interstitial pneumonia is a less frequent manifestation. To minimize side effects, folic acid should be associated with MTX, at the dose of 5–10 mg/week, and administered 24–48 hours after MTX.28 To patients with renal failure, liver disorders, alcoholism, and bone marrow suppression, in addition to women of childbearing age who are not using contraception, MTX is contraindicated. Pregnancy and breast-feeding are formally contraindicated to patients on
MTX, which should be cautiously administered to patients with mild lung disorders, and avoided in individuals with moderate or severe lung impairment.28

b) Sulfasalazine – SSZ
SSZ belongs to the group of salicylates and sulfonamides, being metabolized by intestinal bacteria to sulfapyridine and 5-aminosalicylic acid. Sulfapyridine has several immunomodulatory effects, such as the inhibition of prostaglandin production, of several neutrophilic and lymphocytic functions, and of chemotaxis. It also inhibits folate-dependent enzymes. Its serum concentration peaks in approximately 1.5–6 hours, and its half-life is of 5–10 hours. SSZ is metabolized in the gastrointestinal tract (by the intestinal flora), and excreted through the kidneys (75%–91%).29

SSZ is considered more effective than placebo in reducing disease activity, controlling pain, and for global clinical assessment. Its clinical efficacy and the interference with the radiographic disease progression are confirmed.30 It is usually prescribed at the dose of 1–3 g/day, orally.29,30

The side effects of SSZ are as follows: gastrointestinal intolerance (anorexia, nausea, vomiting), skin rash, elevation in liver enzymes, oral ulcers, and myelosuppression (leukopenia with neutropenia). More rarely, hypersensitivity pneumonia, neurological manifestations, and male fertility changes are observed. Most effects are benign and are reversed with drug suspension.30

SSZ is contraindicated in patients with history of hypersensitivity to sulfa drugs, salicylates or any component of the SSZ formula, and in individuals with porphyria.29,30

c) Leflunomide – LEF
LEF is an immunomodulatory agent with antiproliferative activity that inhibits the enzyme dihydroorotate dehydrogenase, which is involved in pyrimidine synthesis. LEF is absorbed through the gastrointestinal tract, and its biotransformation probably occurs in the liver and gastrointestinal wall, where LEF is mainly transformed into M1, the active metabolite responsible for all the drug’s effects. The concentration of M1 peaks in 6–12 hours, and that metabolite is eliminated through the kidneys and intestines.31

LEF improves disease activity and quality of life, and reduces the radiographic disease progression.32,33 It is prescribed at the dose of 20 mg/day, orally,31–33 but 20 mg on alternate days can be used.

The side effects of LEF include nausea, vomiting, abdominal pain, diarrhea, changes in liver enzymes, skin rash, and SAH.31 It is contraindicated to women of childbearing age who are not using contraception, and to patients with renal failure and liver disorders. Pregnancy and breast-feeding are formally contraindicated to patients on LEF. Its suspension is recommended two years before a possible pregnancy. In case of incidents, especially during pregnancy, LEF can be eliminated by using cholestyramine, at the dosage of 8 g, three times a day, for 11 days.31

d) Antimalarials (chloroquine diphosphate – CQD and hydroxychloroquine sulfate – HCQ)
Antimalarials have been used in the treatment of RA for over 50 years. They are safe and effective, mainly in the early and mild forms of the disease. The mechanism of action is not completely understood, but it seems to involve multiple factors, such as anti-inflammatory activity (stabilization of lysosomal membranes, and inhibition of lysosomal enzymes, and of polymorphonuclear chemotaxis and phagocytosis), and interference with prostaglandin production.34,35

The two available forms of antimalarials are CQD and HCQ, the latter being preferred due to its better safety profile, especially the ophthalmologic one. The maximum daily dose of CQD is 4 mg/kg/day, and of HCQ is 6 mg/kg/day, orally. The drug takes a while to start acting, requiring 3–4 months to reach its peak efficacy in approximately 50% of the patients.

The side effects vary and comprise the following: gastrointestinal intolerance (nausea, vomiting, abdominal pain), skin hyperpigmentation, headache, dizziness, myopathy, and retinopathy. The last side effect is not frequent, but regular ophthalmologic monitoring is indicated (initial assessment, annual assessment after five years, or annual assessment since the beginning, in the presence of risk factors, such as renal or liver dysfunction, maculopathy, advanced age, or cumulative dose greater than 1,000 g for HCQ or 460 g for CQD).36

As compared with placebo, HCQ is effective, reducing the clinical and laboratory parameters (erythrocyte sedimentation rate, ESR) analyzed, although, in isolation, it has not changed the radiographic disease progression.34,35,37 Similar results have been reported with CQD, which is less expensive. Both are contraindicated in patients with alterations of the retina and visual field.36,37

Although antimalarials have been traditionally used in Brazil, often in association with other DMARDs, they are currently considered less potent drugs, and should be used for early RA or undifferentiated arthritis, with low erosive potential.

e) Gold salts
Gold salts, specifically the injectable forms (aurothioglucose and aurothiomalate), can both reduce constitutional and articular symptoms and slow the radiographic progression of RA.38 They can be used in monotherapy or combined with other agents.39

Their usual dose is 50 mg/week, usually beginning with 25 mg/week. The intervals between applications can be increased
to fortnightly and monthly doses after disease control. The cumulative dose should not exceed 3 g.38,39 Their toxicity profile includes myelotoxicity (mainly thrombocytopenia), oral ulcers, skin reactions (exfoliative dermatitis), nephropathy (nephrotic proteinuria can occur), and interstitial pulmonary disease.38,39

Although they have been mentioned in recent international recommendations,20 gold salts are currently rarely used in Brazil, due to their side effects and restricted availability in the country.

**Biologic DMARDs**

One of the most relevant advances in the therapy of RA was the development of biologic DMARDs.40 Although they are effective in controlling RA, their long-term safety has not been established.41

The following biologic DMARDs have been approved by the Brazilian Agency of Sanitary Surveillance (ANVISA) to be used in Brazil:42

- **Anti-TNF agents:** adalimumab, certolizumab, etanercept, infliximab, and golimumab;
- **B lymphocyte depletion agent:** rituximab;
- **T lymphocyte costimulation inhibitor:** abatacept;
- **Interleukin-6 (IL-6) receptor blocker:** tocilizumab.

Biologic DMARDs are indicated to patients with persistent disease activity, despite the treatment with at least two schedules of synthetic DMARDs, of which at least one of them is a combination of DMARD. Biologics should be associated with a DMARD, preferably MTX. Exceptionally, as discussed below, a biologic DMARD can be prescribed earlier in the course of the treatment for RA, especially in cases of disease with signs of poor prognosis (high number of involved joints, radiographic erosions at the initial phase of disease, and high titers of RF and/or anti-CCP).13,20,43–46

Social/educational/demographic characteristics of the different Brazilian macroregions, such as the difficulty in the SC administration of medications experienced by some patients and their families, and the lack of infusion centers for the administration of intravenous (IV) medication in certain areas, can determine the choice of one or other biologic DMARD. The public or private centers of drug dispensation/infusion should instruct patients and their families about the adequate storage of each drug, or send them directly to infusion sites, to prevent loss of treatment efficacy. It is recommended that rheumatologists indicate and monitor the use of those drugs.47

Biologic DMARDs should not be associated because of the potential risk of severe infections.46,49 Currently, anti-TNF agents are the most used biologic DMARDs, but there are evidences that other biologic DMARDs also control RA signs and symptoms and inhibit the radiographic disease progression.

a) **Anti-TNF agents**

TNF is a potent inflammatory cytokine expressed in large amounts in the serum and synovial fluid of individuals with RA. It causes the release of other inflammatory cytokines, particularly interleukins IL-1, IL-6 and IL-8, and stimulates the production of proteases. The inhibition of TNF has proved to be an effective and rapid form to control disease activity.50

In terms of efficacy, there are no data confirming the superiority of any of the five anti-TNF agents approved in Brazil for the treatment of RA.51,52

Anti-TNF agents should be used in association with MTX or other DMARDs, because their combined use proved to be safe and provided rapid benefit in controlling disease activity, as compared with the use of anti-TNF as monotherapy. For patients with contraindications to the use of synthetic DMARDs, anti-TNF agents can be occasionally prescribed as monotherapy.46,53–63

- **Adalimumab – ADA**
  ADA is a human antibody against TNF, prescribed for SC administration at the dose of 40 mg, once every two weeks.55,56,64–68

- **Certolizumab – CERT**
  CERT pegol is a Fab fragment of the humanized anti-TNF antibody, with high affinity with TNF, conjugated with two molecules of polyethylene glycol. It is prescribed for SC administration at the dose of 400 mg every two weeks, or 200 mg every four weeks.61,62,69

- **Etanercept – ETN**
  ETN is a fusion protein composed of the soluble TNF receptor plus the Fc region of IgG, prescribed at a single weekly dose of 50 mg via SC administration.57,58,68,70

- **Infliximab – IFX**
  IFX is a chimeric human-mouse monoclonal anti-TNF antibody, prescribed at the initial dose of 3 mg/kg IV, followed by the same dose (3 mg/kg) in the second and sixth weeks, and then every eight weeks. In patients with insufficient response, the dose can be elevated to 5 mg/kg per infusion, or the interval between doses can be reduced. Higher doses offer little therapeutic benefit and greater risk of infectious complications, and, thus, should be avoided in the treatment of RA.54,59,63,68,71

- **Golimumab – GOL**
  GOL is a monoclonal human anti-TNF antibody administered at the dose of 50 mg, SC, once a month.60,72
Adverse effects and contraindications of the anti-TNF agents

The adverse effects of the anti-TNF agents include infusion reactions for the IV drugs (fever, shivering, chest pain, blood pressure oscillation, dyspnea, pruritus and/or urticaria) and manifestations on the injection sites for the SC drugs (erythema, pruritus, local pain, and/or urticaria). Those drugs increase the likelihood of the following: infections, especially in their first year of use, including severe infections and those caused by intracellular pathogens (tubercle bacillus, listeria, histoplasma, atypical mycobacteria, and legionella); cardiac dysfunction; demyelinating diseases; autoimmune phenomena (autoantibody production); cutaneous vasculitis; interstitial lung disease; and occasional increased risk for lymphoma. Human anti-chimeric antibodies can result from the use of any drug in that class, but their effect on the efficacy of the therapy is uncertain.

The anti-TNF agents are contraindicated to women during pregnancy or breast-feeding, and to patients with the following: New York Heart Association functional classes III and IV congestive heart failure, active infection or high risk for the development of infections (chronic ulcer of the lower limbs, septic arthritis in the last 12 months), recurring lung infections, multiple sclerosis, and current or previous diagnosis of neoplasia (less than five years). Patients should be carefully followed up, with assessment of possible signs of infection, which should be addressed immediately.

Costimulation modulator

Abatacept – ABAT

ABAT is a fusion protein CTLA-4-IgG that inhibits T lymphocyte costimulation. It is indicated to patients with active RA who failed a DMARD or anti-TNF agents. It can be used in association with DMARDs or in monotherapy. ABAT should be administered in IV infusion, for 30 minutes, at the dose of 500 mg in patients weighing less than 60 kg, 750 mg in patients weighing 60–100 kg, and 1,000 mg in patients weighing over 100 kg. The next dose should be administered two to four weeks after the initial dose, and, then, every four weeks.

The use of ABAT has been associated with higher occurrence of infectious complications as compared with placebo, similarly to that observed with other biologic DMARDs. Infusion reactions with ABAT are rare, being mainly hypersensitivity reactions that manifest as exanthem or bronchospasm. It is contraindicated for patients with chronic obstructive pulmonary disease, because of the exacerbation of dyspnea and greater occurrence of infections.

c) B lymphocyte depletion agent

Rituximab – RTX

RTX is a monoclonal chimeric antibody directed against CD20+ lymphocyte, indicated for patients with RA of moderate to severe activity, who failed to respond to an anti-TNF agent. RTX is administered at the dose of 1,000 mg in two IV infusions at a 14-day interval. Sixty minutes before each infusion, 100 mg of methylprednisolone, IV, and 1 g of paracetamol and an antihistamine should be administered to reduce the severity and frequency of infusion reactions.

RTX is preferentially used in association with MTX, and can be prescribed in association with other DMARDs. It is worth noting that a three to four month delay can occur until symptom improvement is observed. Individuals with positive serology for RF and/or anti-CCP show better therapeutic response to RTX. Individuals with good therapeutic response to RTX can undergo a new course of RTX in case of disease reactivation, at a time interval no shorter than six months.

The most frequent adverse events are infusion reactions, which affect 35% of the patients at the first infusion and approximately 10% at the second infusion. In addition, infectious complications, interstitial pneumonia, neutropenia, and thrombocytopenia can occur.

d) Interleukin-6 receptor blocker

Tocilizumab – TOCI

TOCI is a humanized monoclonal antibody that binds the IL-6 receptor, inhibiting the biologic effect of IL-6. It can be used as monotherapy, or in association with MTX or other DMARDs. The incidence of infections and severe infections is equivalent to that of other biologic agents. It is prescribed at the dose of 8 mg/kg, IV, every four weeks.

The dose-dependent side effects of the use of TOCI are as follows: neutropenia; thrombocytopenia; elevation in transaminases, total cholesterol, and low-density lipoprotein; and increased occurrence of infections. It should be avoided in patients at higher risk for intestinal perforation, such as those with diverticular disease of the colon.

Infection in patients on biologic DMARDs

Screening for infectious diseases is recommended before beginning biologic DMARDs, including thorough clinical assessment, serologies for hepatitis B and hepatitis C, and, when pertinent, HIV and/or other endemic diseases. Screening for endemic diseases is better detailed below.
Immunosuppressive drugs

The use of immunosuppressive drugs for the treatment of RA is based on the evidence of multiple immune mechanisms mediating the synovitis and other extra-articular manifestations of the disease. Several mechanisms of action have been described, such as the reduction in cell response (and, less effectively, in humoral response) and anti-inflammatory properties (interference with the migration and action of neutrophils, lymphocytes and monocytes).

The use of immunosuppressive drugs is restricted to the most severe forms of RA, because most of such drugs are considerably toxic (severe myelosuppression, increased occurrence of infections, sterility, urinary bladder toxicity, increased occurrence of neoplasias).

Azathioprine – AZA

Despite its acceptable safety profile, its action as a DMARD remains controversial. AZA is considered a therapeutic option; its lower effect on the control of signs and symptoms and the lack of proof on reduction of the radiographic disease progression, however, make it an alternative only for exceptional cases. The usual dose of AZA is 1–3 mg/kg/day, orally. It is used for treating moderate to severe RA, refractory to other treatments, or for controlling severe extra-articular manifestations, such as vasculitis.

Cyclophosphamide – CF

An alkylating agent with an unfavorable toxicity profile and limited benefit in controlling synovitis, CF can be used either orally (1–2 mg/kg/day) or preferably IV (pulses of 0.5–1 g/m² of body surface). Its use is justified only in severe extra-articular forms, mainly vasculitis.

Cyclosporine – CS

CS is an effective alternative to control the signs and symptoms of RA. It can slow the progression of joint damage even in patients with severe RA refractory to other treatments, although its effect seems to be inferior to that of MTX, SSZ and LEF. It can be used as monotherapy, but is usually prescribed in association with MTX.

Immunomodulation relatively specific to T-lymphocyte has been proposed as the mechanism of action of cyclosporine. It is prescribed orally at the dose of 3–5 mg/kg/day. Cyclosporine is contraindicated in patients with altered renal function, uncontrolled hypertension, and malignancies. Its toxicity, however, limits its use to patients with disease non-responsive to other DMARDs, making it a drug that should only be used in exceptional circumstances for the treatment of RA. It is used preferentially in patients with extra-articular manifestations, such as vasculitis, being a safe alternative for patients with liver disorders and lung involvement. If hypertension or a 30%-increase in baseline creatinine occurs, the cyclosporine dose should be reduced by 25%–50%. If hypertension or increased creatinine persists, the treatment should be discontinued.

THERAPEUTIC STRATEGIES FOR THE TREATMENT OF RA IN BRAZIL

Disease-modifying antirheumatic drugs should be initiated immediately after the diagnosis of RA. Whenever necessary, the treatment should be adjusted at frequent clinical assessments at 30–90-day intervals.

Therapeutic strategies aimed at specific goals produce better clinical outcomes and functional capacity, in addition to lower radiographic structural damage, as compared with conventional treatments. The goal is to reach remission, or at least low disease activity, assessed by use of compound indices of disease activity (CIDA), considering as therapeutic response the reduction in CIDA, according to the 2011 Brazilian Society of Rheumatology consensus for diagnosis and early assessment of RA.

Figure 1 depicts the flowchart of the medicamentous treatment for RA in Brazil, proposed by the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology.

First line – synthetic DMARDs

Methotrexate should be the first-choice DMARD. When contraindicated, SSZ or LEF can be used as the first option. The use of antimalarials (CQD and HCQ) can be indicated only for patients with mild disease or undifferentiated arthritis with low erosive potential. In exceptional cases, such as patients with hypersensitivity to other DMARDs, or with viral hepatitis, gold salts can be used. MTX should be preferentially prescribed in monotherapy, at the beginning of treatment.

When the aimed clinical response (remission or low disease activity) is not obtained with the maximum tolerated dose of MTX, or in the presence of adverse effects, change to another DMARD as monotherapy or use of DMARD combinations is recommended. The most used combinations of MTX are with the following: CQD/HCQ, SSZ, an association of those three drugs, and LEF. The progression of therapy should be rapid, with monthly assessments in the first six months of treatment, and adjustment of the dosing schedules as required. A maximum period of six months should be observed to define lack of response to the first-line treatment instituted.
**Table 1**

Disease-modifying antirheumatic drugs used for treating rheumatoid arthritis in Brazil

<table>
<thead>
<tr>
<th>Drug</th>
<th>Presentation</th>
<th>Dose</th>
<th>Clinical response and monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synthetic disease-modifying antirheumatic drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Tablets: 2.5 mg Solution for injection: 50 mg/2 mL</td>
<td>10–30 mg/week (orally, IM or SC)</td>
<td>Reduces signs and symptoms of disease activity, improves the functional status, and reduces the radiographic disease progression. Currently considered the standard drug for treating RA. Monitoring: blood count, creatinine and liver enzymes every 4–12 weeks.</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>Tablets: 500 mg</td>
<td>1–3 g/day (orally)</td>
<td>Reduces signs and symptoms of disease activity, improves the functional status, and reduces the radiographic disease progression. Monitoring: blood count and liver enzymes every 8–12 weeks. Can be associated with MTX and other DMARDs.</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>Tablets: 500 mg</td>
<td>20 mg/day or alternate days (orally)</td>
<td>Reduces signs and symptoms of disease activity, improves the functional status, and reduces the radiographic disease progression. Monitoring: blood count, creatinine and liver enzymes every 4–12 weeks. Can be associated with MTX and other DMARDs.</td>
</tr>
<tr>
<td>Hydroxychloroquine sulfate</td>
<td>Tablets: 400 mg</td>
<td>Up to 6 mg/kg/day (orally)</td>
<td>Antimalarials are currently considered less potent drugs, and should be used at initial cases of RA or undifferentiated arthritis, with low erosive potential. Can be associated with MTX and other DMARDs. Monitoring: initial ophthalmologic exam and annually after five years (or annually since the beginning, in the presence of risk factors for maculopathy or retinopathy).</td>
</tr>
<tr>
<td>Chloroquine dihydrophosphate</td>
<td>Tablets or capsules: 150 mg or 250 mg</td>
<td>Up to 4 mg/kg/day (orally)</td>
<td>Effective in controlling symptoms and reducing the radiographic disease progression, rarely used in Brazil, due to their adverse effects and low availability. Monitoring: monthly; blood count, liver enzymes, and urinalysis.</td>
</tr>
<tr>
<td>Sais de ouro (aurotioglicose ou aurotiomalato de sódio)</td>
<td>Solução injetável: 50 mg/0.5 mL</td>
<td>50 mg/week, deeply IM, usually initiating with 25 mg/week. After control, fortnightly and monthly doses. The cumulative dose should not exceed 3 g</td>
<td>Effective in controlling symptoms and reducing the radiographic disease progression, rarely used in Brazil, due to their adverse effects and low availability. Monitoring: monthly; blood count, liver enzymes, and urinalysis.</td>
</tr>
</tbody>
</table>

<p>| <strong>Biologic disease-modifying antirheumatic drugs</strong> | | | |
| Tumor necrosis factor blockers | | | |
| <strong>Adalimumab</strong> | Prefilled syringes: 40 mg | 40 mg SC every 15 days | Effective in controlling symptoms and reducing the radiographic disease progression. Should be preferably prescribed after failure of two schedules with synthetic DMARDs (one of which should include the combination with synthetic DMARDs, with MTX preferably as the anchor drug), associated with MTX or other synthetic DMARD. Monitoring: investigation of latent TB before starting treatment (clinical history, chest radiography, PPD and/or IGRA), blood count, liver enzymes every 4–12 weeks. Careful monitoring of the occurrence of infection, particularly during the first year of use. |
| <strong>Certolizumab</strong> | Prefilled syringes: 200 mg | 400 mg SC every two weeks, in weeks 0, 2, and 4, and, then, 200 mg every two weeks, or 400 mg every four weeks | |
| <strong>Etanercept</strong> | 25-mg and 50-mg vials or 50-mg prefilled syringes | 50 mg/week | |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Presentation</th>
<th>Dose</th>
<th>Clinical response and monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infliximab</strong></td>
<td>Vials: 100 mg</td>
<td>3–5 mg/kg/dose IV infusion in weeks 0, 2 and 6, followed by the same dose every 6–8 weeks</td>
<td>Eficaz na redução de sinais e sintomas da AR e na redução da progressão radiográfica. Pode ser prescrito após falha de DMCD sintéticas ou após falha e/ou intolerância a DMCD biológicas. Uso preferencial associado ao MTX ou outras DMCD sintéticas. Monitoração: hemograma e enzimas hepáticas a cada 4–8 semanas. Monitorar ocorrência de infecção.</td>
</tr>
<tr>
<td><strong>Golimumab</strong></td>
<td>Prefilled pen: 50 mg</td>
<td>50 mg SC monthly</td>
<td></td>
</tr>
<tr>
<td><strong>Costimulation modulator</strong></td>
<td>IV infusion of 500 mg in patients weighing less than 60 kg, of 750 mg in patients weighing 60-100 kg, and of 1,000 mg in patients over 100 kg, every four weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Abatacept</strong></td>
<td>250-mg vials</td>
<td>500 mg to 1 g IV on days 0 and 14 (1–2 g/cycle)</td>
<td>Effective in reducing signs and symptoms of RA and the radiographic disease progression. Can be prescribed after failure of anti-TNF or other biologic DMARDs. It should not be prescribed after failure of synthetic DMARDs, except for exceptional situations. The presence of RF and/or anti-CCP predicts better therapeutic response to RTX. It should be preferably prescribed in association with MTX or other synthetic DMARD. The cycles can be repeated at minimum intervals of six months, according to disease evolution. Monitoring: blood count and liver enzymes every 4–12 weeks. Occurrence of infection should be assessed.</td>
</tr>
<tr>
<td><strong>B lymphocyte depletion agent</strong></td>
<td>500-mg vials</td>
<td>8 mg/kg/dose on IV infusion every four weeks</td>
<td>Effective in reducing signs and symptoms of RA and the radiographic disease progression. Can be prescribed after failure of synthetic DMARDs or failure of and/or intolerance to anti-TNF or other biologic DMARDs. Preferential use in association with MTX or other synthetic DMARDs, although it can be used as monotherapy. Monitoring: blood count, liver enzymes, and lipid profile at every infusion.</td>
</tr>
<tr>
<td><strong>Rituximab</strong></td>
<td>80-mg or 200-mg vials</td>
<td>8 mg/kg/dose on IV infusion every four weeks</td>
<td></td>
</tr>
<tr>
<td><strong>Tocilizumab</strong></td>
<td>500-mg vials</td>
<td>80-mg or 100-mg vials</td>
<td></td>
</tr>
</tbody>
</table>

**Immunosuppressive drugs**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Presentation</th>
<th>Dose</th>
<th>Clinical response and monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azathioprine</td>
<td>Tablets: 50 mg</td>
<td>1–3 mg/kg/day, orally</td>
<td>Monitoring: blood count and liver enzymes every 4–8 weeks.</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Tablets: 50 mg</td>
<td>2–2.5 mg/kg/day, orally, or monthly pulse therapy with 750 mg to 1 g/m² of body surface, IV every four weeks</td>
<td>Reserved for patients with severe extra-articular manifestations. Monitoring: blood count, liver enzymes, and urinalysis (due to the risk of hemorrhagic cystitis) every four weeks.</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Tablets: 50 mg and 100 mg</td>
<td>3–5.0 mg/kg/day (orally)</td>
<td>Blood pressure and renal function every 2–4 weeks.</td>
</tr>
</tbody>
</table>

Low doses of corticoids (maximum of 15 mg/day of prednisone or equivalent), as well as anti-inflammatory drugs, can be used at the beginning of treatment; however, caution and the use for the shortest time possible to reduce the occurrence of adverse effects are recommended.20

Second line – biologic DMARDs
Immunobiologic therapy for RA is indicated for patients with persistently moderate to high disease activity (according to CIDA), despite the use of at least two of the schedules proposed in the first-line treatment. Of the biologics, anti-TNF drugs are the first choice in Brazil after the schedules with synthetic DMARDs fail. That is justified by the more comprehensive post-commercialization experience, and the greater volume of safety information originating from national104 and international20 clinical trials, registries, and recommendations. However, other drugs, such as ABAT and TOCI, can be prescribed at the physician’s discretion after failure of the synthetic DMARD, based on the publication of randomized clinical trials.78,89 RTX should be avoided as a first-choice biologic,20 except for the following specific cases: patients with contraindication to other biologics, preferentially those positive to RF and/or anti-CCP, and those diagnosed with associated lymphoma.

On exceptional situations, a biologic DMARD can be indicated after failure of the first synthetic DMARD schedule for patients with several factors of poor prognosis, such as very intense disease activity, elevated number of tender/inflamed joints, high titers of RF and/or anti-CCP, and early occurrence of radiographic erosions.20 The worse prognosis factors are better detailed in the 2011 Brazilian Society of Rheumatology Consensus for diagnosis and early assessment of RA.5

Biologic DMARDs are not recommended as first-line treatment for RA in Brazil, because there is no evidence of cost-effectiveness in that country.

Third line – failure of biologic DMARDs or intolerance to them
In the clinical settings of no response to the initial biologic treatment, evolution to loss of the response obtained, or presence of important adverse events, one biologic agent can be exchanged for another. The biologics that showed benefits on randomized clinical trials with patients who failed anti-TNF agents were ABAT, RTX, and TOCI.105 Patients who failed the first anti-TNF agent have also shown to benefit from the use of a second drug of the same class, such as ADA, CERT, ETN, IFX, or GOL, in prospective observational studies and also in double-blind controlled randomized trials (GOL), but the magnitude of their therapeutic effects and cost-effectiveness of that strategy remain controversial.106

The choice of the treatment sequence to be applied is at the physician’s discretion, depending on the particularities of each case. A minimum period of three months and maximum of six months of clinical assessment is recommended prior to exchanging the therapeutic schedule (exchange between biologic DMARDs).

Medication withdrawal and occasional therapy suspension
Data defining the duration of the therapy for RA still lack. Currently, the medication indicated and to which the patient responds properly should be maintained indefinitely, at the physician’s discretion. In case of complete (remission) and sustained (for more than 6–12 months) response, gradual and careful drug withdrawal can be attempted at the following sequence: at first, NSAIDs; then, corticoids and biologic DMARDs; synthetic DMARDs should be maintained.107 Exceptionally, if remission persists, the synthetic DMARD withdrawal can be carefully attempted.20 Drug-free sustained remission is rare, especially in patients with biomarkers such as anti-CCP and/or RF.

Treatment monitoring
Regarding early disease, for patients with active disease and symptoms up to one year, intensive follow-up is recommended with monthly visits and rapid medicamentous progression, when necessary.108,109 Therapeutic schedules and their possible adverse effects have already been approached in the previous sections.

At every visit, the efficacy and safety of the therapeutic intervention should be assessed, considering the patient’s comorbidities and aiming preferentially at remission or the lowest possible disease activity, as well as the improvement in functional capacity and quality of life. For patients with established disease, and especially those with controlled disease, the visits can be performed every three months.108,109

Table 2 shows the monitoring frequency of the major parameters for properly assessing patients with RA undergoing treatment.
Physical therapy and rehabilitation

During the phases of disease activity, rest helps to reduce the inflammatory process; however, the possibility of complications, such as joint stiffness and flexion deformities, should be considered.110

Kinesiotherapy can comprise passive exercises, in the initial phases, and active, isometric and/or isotonic, exercises. Those exercise programs are aimed at assuring maintenance, restoration, or gain of joint range of motion, muscle strength and stretching, aerobic capacity, and performance of specific abilities.110

Most programs of dynamic exercises follow the recommendations of the American College of Sports Medicine (ACSM).111 We recommend at least 20 minutes of exercise, at least twice a week, which leads to a 60% increase in the heart rate predicted for age, so that it can provide positive clinical effects with neither worsening RA activity nor causing pain. When dynamic exercise is compared with the conventional joint rehabilitation program, a significant increase in the quality of life of patients with RA is observed.112–114

Aerobic activities, such as bicycle riding, jogging, running, water aerobics, and swimming provide better cardiovascular

Figure 1
Flowchart for the medicamentous treatment of RA.
### Table 2
Monitoring the treatment of rheumatoid arthritis

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Initial assessment</th>
<th>Monthly assessment (early RA)</th>
<th>Extra consultations</th>
<th>Assessment every three months (established RA)</th>
<th>Annual assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education of patients and families</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CIDA⁺</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>mHAQ or HAQ-DI (0–3 points)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X (minimum reduction desired: 0.22 points)</td>
</tr>
<tr>
<td>RF/anti-CCP</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>(if negative at the first assessment, they can be repeated in the two initial years)</td>
</tr>
<tr>
<td>Conventional radiography (hands and wrists, feet and ankles, other joints affected)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Joint resonance or ultrasound (in doubt regarding the synovitis)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>*Assessment of extra-articular manifestations</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>**Assessment of comorbidities</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Inflammatory activity tests (ESR and CRP)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>**Laboratory assessment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vaccination assessment</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>**** Specific medicamentous treatment for RA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medicamentous treatment of comorbidities</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PPD (or IGRA) and chest radiography (if a biologic DMARD, specially anti-TNF, is prescribed)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Occupational therapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Rehabilitation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Evaluation of orthotic indication</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Evaluation of surgical indication</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Coordination of the multidisciplinary team</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Gestational counseling</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Evaluation of infections (clinical assessment and occasional complementary exams)</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>****Evaluation and education regarding emergency situations</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

CIDA: compound indices of disease activity (SDAI – simple disease activity index; CDAI – clinical disease activity index; DAS28 – disease activity score - 28 joints); +: for CIDA goals, see the 2011 BSR Consensus for diagnosis and early assessment of RA; mHAQ: modified health assessment questionnaire; HAQ-DI: health assessment questionnaire - disability index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PPD: tuberculin skin test; IGRA: interferon gamma release assays.

* Extra-articular manifestations: rheumatoid nodules, interstitial lung disease, serositis, ocular inflammation, and vasculitides.
**Comorbidities: arterial hypertension, cardiovascular ischemia, diabetes mellitus, atherosclerosis, low bone mass, depression, fibromyalgia, etc.
***Laboratory exams: blood count, liver function, lipid profile, and renal function; depending on the comorbidities, consider additional exams.
****Medication for RA: consider the efficacy and safety issues of each medication detailed throughout the text.
*****Urgencies on RA: scleromalacia perforans, myelopathies, multiple mononeuritis and vasculitis, pregnant patients on teratogenic drugs.
conditioning and can aid to prevent RA-related limitation.\textsuperscript{110} Physical means can be used as adjuncts to control pain, muscle contraction, and joint stiffness.\textsuperscript{115–119}

**Occupational therapy**

Occupational therapy uses several techniques for joint protection and energy conservation. The treatment is aimed at reducing pain by planning stimulation activities, regular rest, joint motion pattern alternation, and use of orthoses and other devices.\textsuperscript{120}

Adaptations in the household and work environment help to preserve the independence of individuals with RA-related limitations.\textsuperscript{121}

Orthosis is any medical device applied to the patient’s body to support, align, position, immobilize, prevent or correct deformities, help with muscle strength or improve joint function. Orthoses reduce pain and local inflammation by relieving tension and load on a certain joint.\textsuperscript{121,122} The use of rest orthoses/braces, such as wrist brace, prevents flexion contractures. Functional wrist braces should be used intermittently during activities for movement restriction, aiming at joint protection.\textsuperscript{123} Spinal orthoses are indicated to limit motion, especially flexion, with consequent reduction in pain, muscle tension and paresthesia in cases of atlantoaxial subluxation.\textsuperscript{120}

**Surgical treatment**

Properly indicated surgical treatment contributes to improve function, mobility, pain control, and quality of life of patients with RA. The surgical procedures comprise the following: synovectomy, release of compressive neuropathies (carpal tunnel), tendon repair with muscle, total arthroplasty, and stabilization of cervical unstable vertebrae.\textsuperscript{124,125}

**Radiation synovectomy**

Yttrium-90 (Y-90) or samarium-153 (Sm-153 PHYP) radiation synovectomy can be indicated, as an alternative to surgical synovectomy, for patients with residual synovitis in a few joints despite the optimization of other treatments instituted.\textsuperscript{126}

**Alternative therapies**

Patients with chronic diseases, such as RA, frequently seek alternative therapies, and sometimes to the detriment of the traditional treatment. Those therapies include diets, meditation, biofeedback, acupuncture, massages, chiropractic, and homeopathy. Most of the time, scientific studies about the safety and efficacy of those treatments lack.\textsuperscript{127}

Patients should be instructed to always consult with their physicians before beginning one of those therapies. It is up to the physician to assess whether the intended alternative treatment can harm the patient, and it is the physician’s responsibility to instruct the patient that those methods should not replace the traditional therapy for RA.

**Managing comorbidities**

Comorbidities in patients with RA are frequent and comprise SAH, type 2 diabetes mellitus, dyslipidemia, and osteoporosis.\textsuperscript{128–130} In addition, neoplasias, infections and lung diseases, such as bronchiectasis and interstitial pneumonitis, are also more prevalent in those patients.\textsuperscript{131–134} The presence of those comorbidities contributes to poor quality of life and increases the mortality of patients with RA; thus, comorbidities should be diagnosed and treated in the initial phase of the disease.\textsuperscript{135} The management of comorbidities will be reviewed in a specific recommendation by the BSR.

**Treatment of the extra-articular manifestations of rheumatoid arthritis**

The treatment of the majority of severe extra-articular manifestations of RA (rheumatoid vasculitis, scleritis, some histological subtypes of interstitial lung disease, recalcitrant serositis) includes systemic corticoids (oral or venous) and immunosuppressive drugs, such as CF, CS, and AZA.\textsuperscript{136} Anecdotal evidence of clinical improvement of cases of rheumatoid vasculitis and lung involvement have been reported, but are conflicting and lack confirming studies.

**Autologous cell transplantation**

So far, conclusive data confirming the role of hematopoietic stem-cell transplantation as inductor of prolonged RA remission in the adult still lack.\textsuperscript{137} Because the toxicity and mortality associated with the procedure are still significant, autologous cell transplantation in Brazil is reserved to severe forms, with multiple extra-articular manifestations, refractory to the treatments instituted and with risk of death.
PHARMACOECONOMICS’ CONSIDERATIONS OF RHEUMATOID ARTHRITIS TREATMENT IN BRAZIL

The introduction of potent biologic DMARDs has widened the alternatives for the effective treatment of RA. However, those drugs have substantially high costs as compared with those of traditional synthetic DMARDs, competing with the limited health resources in other essential interventions.

In general, the use of MTX, SSZ, and LEF in patients with active RA with no previous treatment with DMARDs has proved to be cost-effective as compared with the use of NSAIDs and corticoids in international studies. However, the use of biologic therapy in monotherapy or in combination with MTX in those patients is not cost-effective as compared with MTX in monotherapy.

After failing the first synthetic DMARD, the introduction of LEF can be a cost-effective strategy, because it delays the use of biologics. Similar data can be found in the Brazilian literature. A study using an economic model with Markov’s principle has reported that the use of MTX in monotherapy was the most cost-effective therapy in a 48-month period.

When the treatment with anti-TNF agents fails, RTX and ABAT can be cost-effective. However, regarding the use of second and third anti-TNF agents, in that context, there are no randomized clinical trials providing cost-effectiveness analysis.

Regarding the reality of the Brazilian rheumatological practice, Ferraz et al. have published the results of a questionnaire applied to Brazilian rheumatologists about the RA diagnosis and treatment. Those authors have reported that approximately 50% of the patients with RA are being properly diagnosed, and that only half of them are undergoing regular treatment. The therapeutic practice in public and private health care services has not varied markedly. At both types of health care services, the most commonly used combination therapy (two or more DMARDs) was the MTX + CQD association, followed by MTX + CQD + SSZ at the public service, and MTX + LEF at the private service. When those agents failed, the most used biologic agent was IFX, probably because it was the only therapeutic option in the Brazilian Unified Public Health Care System (SUS) during the period studied. The major difficulties identified in the patients’ treatment were their access to the public health care system and the cost of the medication in the private system. Other challenging aspects for the proper management of patients with RA at national level are the regional differences in access to health care services, the heterogeneous distribution of rheumatologists in the Brazilian territory, and the few specialized services available.

Pharmacoeconomic studies based on the Brazilian reality need to be developed to generate information that can rationally guide decision making in the treatment of patients with RA.

SPECIAL SITUATIONS

Rheumatoid arthritis and pregnancy

RA by itself does not alter fertility, although some medications can reduce the ovulation rate. In addition, neither fetal nor maternal complications due to RA are increased, except in the severe forms that evolve with systemic vasculitis.

During the gestational period, the clinical manifestations of RA usually improve in up to 75% of the patients, although 90% relapse in the first six puerperal months.

Most drugs used in the RA treatment are contraindicated during pregnancy and breast-feeding, except for HCQ and SSZ, which seem to be relatively safe. Patients on MTX, LEF, immunosuppressive agents, and biologic DMARDs should be instructed to use safe contraceptive methods to prevent pregnancy.

Rheumatoid arthritis and vaccination

The overall risk of infection is known to be increased in RA, particularly for patients on immunobiologic agents. Thus, the need for vaccinating those patients should be considered. Before starting synthetic or biologic DMARDs, the patient’s vaccination status should be assessed and updated.

Vaccines that do not contain living organisms, such as the following, can be safely administered, and preferably 14 days before starting medication: anti-influenza (IM), pneumococcal (7V and 23V), tetanus, diphtheria, pertussis, haemophilus influenzae type B, viral hepatitis A and B, poliomyelitis (inactive – IPV), meningococcal, HPV, typhoid fever (IM), and rabies. In a more systematic manner, most protocols recommend the administration of at least the following vaccines before starting...
therapy with biologic DMARDs: influenza (seasonal, annually, from April to September) and pneumococcal (initially, and booster dose after five years).154

Vaccines containing living organisms are contraindicated during immunosuppression and at least for three months after using such drugs. That group of vaccines includes the following: MMR (measles, mumps and rubella), BCG, influenza (nasal), varicella-zoster, typhoid fever, poliomyelitis (oral – OPV), smallpox, and yellow fever.154 However, some specific situations, such as the indication of the yellow fever vaccine for the population living in endemic areas of the disease, should be considered.155,156

It is worth noting that vaccines, when indicated, should be administered preferably before the treatment with immunosuppressive agents or biologic DMARDs, because the response to the vaccine might be decreased.153

The management of vaccination in patients with RA will be reviewed in a specific recommendation of the BSR.

Brazilian endemic diseases

Endemic-epidemic transmissible diseases, such as tuberculosis infection (TB), leprosy, malaria, Chagas’ disease, schistosomiasis, yellow fever, dengue, filariasis, helminth infections, hepatitis B and hepatitis C, are still a relevant problem of public health in Brazil.157

Although there are few studies on the relationship between infectious-contagious endemicities and RA, it is worth considering that those conditions can affect both the diagnosis (sometimes mimicking,5 other times superimposing to the joint and systemic symptoms of RA, in addition to the possible occurrence of serological markers, such as anti-CCP and RF, in infectious diseases158) and the management of RA. The use of immunosuppressive therapies, especially biologic DMARDs, should be carefully assessed in specific situations.159

Because of the high prevalence of TB in Brazil and the reports about TB reactivation during immunosuppressive treatment,164,165–166 biologic DMARDs should be carefully used in patients with susceptibility to TB or previous history of TB. All patients should undergo chest radiography and tuberculin skin test (PPD) before starting therapy.165

The risk is higher with the use of anti-TNF therapy, especially monoclonal antibodies.166 Brazil lacks controlled studies on the cost-effectiveness of performing PPD in two steps to assess the “booster” phenomenon in patients with RA who will undergo biologic therapy. The PPD can be negative in patients with RA due to their underlying immune disorder or the used therapy.167 Although in vitro interferon gamma release assays (IGRA), such as Quantiferon® or Elispot®, are promising,168–170 because they are more specific, their role in investigating latent TB in Brazil is yet to be defined.168–171

The use of chest high resolution computed tomography to investigate latent TB should be assessed in each case. The treatment of latent TB forms with isoniazid at the dose of 5–10 mg/kg/day up to the maximum dose of 300 mg/day, for six months, should be performed in patients with the following characteristics: PPD reading ≥ 5 mm (or positive IGRA), radiological changes compatible with previous TB, or in patients that have had close contact with individuals with active TB.165,172–174 The treatment of latent TB forms should be initiated at least one month before starting the biologic DMARD. Exceptionally, however, their beginning can be concomitant, when the inflammatory disease activity requires urgency in introducing the biologic therapy. Although, so far, studies have not shown an increase in the occurrence of TB cases with the use of non-anti-TNF biologic DMARDs, screening for latent infection is recommended.

In addition to HIV, viral hepatitis B and viral hepatitis C should be investigated prior to the use of biologic DMARDs. If those viral infections are present, biologic DMARDs should be avoided. In exceptional cases of infection by hepatitis C virus, biologic DMARDs can be used associated with the antiviral treatment.175,176

Specific infections, such as Chagas’ disease, should be investigated in endemic regions. In addition, routine dental assessment and care are recommended before and during treatment, for the prevention and treatment of periodontal infections.177

BSR RECOMMENDATIONS FOR TREATING RHEUMATOID ARTHRITIS

Based on the above considerations and on the peculiar aspects of the Brazilian socioeconomic reality, the expert members of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology have proposed the recommendations summarized in Table 3 for treating patients diagnosed with RA.
Recommendation 1: Before any type of treatment, patients should be instructed about their disease, and, particularly, about the possible evolution and prognosis. The treatment decision should be shared with patients.

Recommendation 2: Immediately after the diagnosis, a DMARD should be prescribed and the treatment should be adjusted aiming at achieving remission or low disease activity (according to CIDA) at frequent clinical assessments, within 30–90 days.

Recommendation 3: The treatment for RA should be conducted by a rheumatologist, who is the specialist with the greatest knowledge about the therapeutic options available, their indications and adverse effects.

Recommendation 4: The first-line treatment comprises synthetic DMARDs, such as MTX, LEF, and SSZ. The antimalarials HCQ and CQD are less effective and should be reserved for mild disease forms and with low erosive potential. CS or parenteral gold can be used on exceptional conditions.

Recommendation 5: MTX is the drug of choice for treating RA, but, if contraindicated and/or at the physician’s discretion, other synthetic DMARDs can be used as first choice. Combinations of synthetic DMARDs can be prescribed, even as the first option, for established RA with predictors of poor prognosis.

Recommendation 6: Patients who failed to achieve a response, characterized as clinical remission or at least low disease activity (according to assessment by use of one of the CIDA) after at least two schemes of synthetic DMARDs, including at least one combination of synthetic DMARDs, should be assessed regarding the use of biologic DMARDs.

Recommendation 7: Exceptionally, for patients combining characteristics of worse prognosis and rapidly progressive disease, biologic DMARDs can be considered after one single scheme of synthetic DMARDs.

Recommendation 8: The use of anti-TNF agents (ADA, CERT, ETN, IFX, or GOL) is preferentially recommended as initial biologic therapy. However, in the presence of contraindications or in certain clinical situations, biologic therapy can be initiated with other biologic DMARDs, such as B lymphocyte depletion agents (RTX), T lymphocyte costimulation modulators (ABAT), and antibodies against the IL-6 receptor (TOCI).

Recommendation 9: After therapeutic failure to respond to the first biologic DMARD (anti-TNF or not), other biologic DMARDs (anti-TNF or not) can be used. It is up to the physician to choose the biologic DMARD to be used in patients who failed to respond to a biologic DMARD.

Recommendation 10: CF and AZA can be used in patients with severe extra-articular manifestations, such as vasculitis and/or lung involvement.

Recommendation 11: The intra-articular use of a corticoid is useful at any time during treatment. The oral use of a corticoid has a DMARD effect and improves the clinical response at the initial phase, but it should be used at low doses (< 15 mg/day of prednisone or equivalent) and for the shortest period of time necessary.

Recommendation 12: NSAIDs are useful to reduce the inflammatory process and pain, mainly at the initial phase of disease, but should always be prescribed in association with a DMARD.

Recommendation 13: At the beginning of the RA treatment, the patient should be preferably assessed monthly. Patients whose disease is under control can be assessed at longer intervals of up to three months.

Recommendation 14: Physical therapy, rehabilitation and occupational therapy are indicated from the patient’s initial assessment onwards.

Recommendation 15: Surgical treatment, when properly and opportunistically indicated, contributes to improve the function, motion, pain control, and quality of life of patients with RA.

Recommendation 16: It is recommended that patients be instructed to always consult with their physician before starting an alternative therapy (acupuncture, diet therapy, homeopathy, phytotherapy). The physician should assess whether the intended alternative treatment can induce any damage to the patient and instruct him/her not to replace traditional therapy for RA with the alternative therapy.

Recommendation 17: Patients should be educated regarding family planning, adequate time for pregnancy (based on disease activity and use of medications), and effective contraceptive methods for women on teratogenic drugs, such as MTX and LEF.

Recommendation 18: The active search for and adequate management of comorbidities (SAH, diabetes mellitus, dyslipidemia) should be performed, because comorbidities contribute to decrease the quality of life and increase the mortality of patients with RA.

Recommendation 19: Before initiating synthetic or biologic DMARDs, the patient’s vaccination chart should be assessed, and the indicated vaccines should be administered, preferably prior to treatment with immunosuppressors or biologic agents, because the response to vaccine can be reduced.

Recommendation 20: Endemic-epidemic transmissible diseases in Brazil, such as tuberculosis infection, leprosy, malaria, Chagas’ disease, schistosomiasis, yellow fever, dengue, filariasis, and helminth infections, should be assessed and properly treated in patients with RA.

CONCLUSIONS

This consensus aimed at elaborating recommendations for the treatment of RA in Brazil, considering the characteristics of the country, such as drug availability, socioeconomic level of the population, pharmacoeconomic aspects, and the occurrence of several endemic diseases.

Despite the recent publication of the North-American and European guidelines for the treatment of RA, it is worth reviewing the subject, considering specific aspects of the Brazilian reality. Thus, the finality of establishing consensual guidelines for treating RA in Brazil is to support Brazilian rheumatologists, by using the evidence obtained in scientific studies and the experience of an expert committee to homogenize the therapeutic approach of RA, within the Brazilian socioeconomic context, maintaining the physician’s autonomy to indicate/choose between the therapeutic alternatives available.

Because of the rapid advance of knowledge in the science field, we suggest these recommendations be updated every two years.
Conflicts of interest:

1. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the pharmaceutical industry (PI): Roche and Mantecorp; has received personal or institutional support from the PI (Abbott, AstraZeneca, MSD, Roche and Pfizer); has delivered speeches at events related to this consensus and sponsored by the PI (Abbott, AstraZeneca, Janssen, MSD, Mantecorp, Roche and Pfizer). Is a member of the Advisory Board for the PI or regulatory committees of scientific studies sponsored by the PI (AstraZeneca and MSD). Has elaborated scientific texts for periodicals sponsored by the PI (Abbott and Pfizer).

2. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the PI (Roche); has received personal or institutional support from the PI (Abbott, BMS, Mantecorp, MSD, Novartis, Roche, Wyeth and Pfizer); has delivered speeches at events related to this consensus and sponsored by the PI (Abbott, MSD, Novartis, Roche and Wyeth).

3. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the PI (BMS, Pfizer, Roche and Wyeth); has received personal or institutional support from the PI (Abbott, BMS, Mantecorp, Roche and Wyeth); has delivered speeches at events related to this consensus and sponsored by the PI (Abbott and Roche).

4. Has received personal or institutional support from the PI (Abbott, MSD, Janssen, Roche, BMS and Pfizer); has delivered speeches at events related to this consensus and sponsored by the PI (Abbott, MSD, Janssen, Roche, BMS and Pfizer). Is a member of the Advisory Board for the PI or regulatory committees of scientific studies sponsored by the PI (Pfizer, Abbott, MSD and BMS).

5. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the PI (BMS, Pfizer and Roche); has received personal or institutional support from the PI (Abbott, MSD, Wyeth, Pfizer and Roche); has delivered speeches at events related to this consensus sponsored by the PI (Wyeth, Pfizer and Abbott). Is a member of the Advisory Board for the PI or regulatory committees of scientific studies sponsored by the PI (Wyeth, MSD and AstraZeneca). Has elaborated scientific texts for periodicals sponsored by the PI (Abbott, Wyeth, BMS and AstraZeneca).

6. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the PI (BMS and Roche); has received personal or institutional support from the PI (Roche, MSD, Wyeth, Pfizer and Abbott); has delivered speeches at events related to this consensus and sponsored by the PI (Roche, MSD, Janssen, and Mantecorp).

7. The author declares no conflict of interest.

8. Has delivered speeches at events related to this consensus and sponsored by the PI (Roche and BMS). Is a member of the Advisory Board for the PI or regulatory committees of scientific studies sponsored by the PI (Roche and BMS).

9. Has delivered speeches at events related to this consensus and sponsored by the PI (Roche and BMS). Is a member of the Advisory Board for the PI or regulatory committees of scientific studies sponsored by the PI (Roche and Mantecorp).

10. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the PI (Roche and BMS); has received personal or institutional support from the PI (Roche, MSD, Wyeth, Pfizer and Abbott); has delivered speeches at events related to this consensus and sponsored by the PI (Roche and Janssen-Cilag).

11. Has participated in clinical and/or experimental studies related to this consensus and sponsored by the PI (Roche and Mantecorp); has received personal or institutional support from the PI (Lilly, Pfizer and Actelion); has delivered speeches at events related to this consensus and sponsored by the PI (Lilly, Pfizer and Actelion). Is a member of the Advisory Board for the PI or regulatory committees of scientific studies sponsored by the PI (MSD).

12. Has received personal or institutional support from the PI (Roche and Janssen-Cilag).
REFERENCES


47. Mohohora S, Inoue E, Ikari K, Yano K, Tokita A, Honjo Y et al. Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol 2011 Jul 15; [Epub ahead of print]


